Mumbai based Glenmark Pharmaceuticals on Thursday said it had filed for approval to start initial stage clinical trials of experimental biological drug GBR 500. The company has filed for approval with the US Food and Drug Administration, it informed Bombay Stock Exchange.
Glenmark hopes to develop this drug as a treatment for multiple sclerosis. The company said that it expects to complete the trial in the current financial year.
Biological drugs are developed from larger molecules developed from living organism. It is considered more difficult to develop vis a vis smaller chemical molecules.